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been well characterized. The purpose of this review is to raise awareness of ethanol use as an excipient in
neonatal and infant medications and to provide insight, based on the available evidence, into clearance
rates of ethanol in babies. We also discuss ethanol pharmacokinetics in adults, theoretical pharmaco-
kinetic changes in neonates and infants as it may apply to ethanol disposition, and case reports involving
ethanol exposure in neonates and infants.
Materials and methods: This study was a narrative review in which relevant papers were selected using
databases and scientiﬁc search engines such as PubMed with the key words ethanol, infant, and newborn
infant.
Results: It remains unclear what ethanol exposure is safe for neonates and infants. The Food and Drug
Administration and American Academy of Pediatrics have both taken action, by either setting limits of
ethanol content in over-the-counter medications or by recommending restricted exposure to ethanol-
containing pediatric formulations.
Conclusions: Until the short- and long-term health effects of chronic ethanol administration can be
further characterized, ethanol-containing medications should be used with caution.
& 2014. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).Introduction
Ethanol, also known as alcohol or ethyl alcohol, has been used
medicinally and recreationally for centuries, and its pharmacoki-
netic properties have been studied widely for medical, legal, and
forensic purposes. Ethanol serves as a solvent and a microbial
preservative in oral liquid medications and is the second most
commonly used solvent in liquid formulations following water.1,2
Often used to dissolve water-insoluble ingredients, it can be found
in medicinal solutions, elixirs, and spirits. Table I shows some
examples of commonly prescribed oral ethanol-containing medi-
cations in the United States, and their respective ethanol contents.
Ethanol can also be found in parenteral formulations and functions
as a co-solvent.
Despite widespread use of ethanol in medications for neonates
and infants, the pharmacokinetics and safety of this pharmacolog-
ically active agent are not well described. There is limited infor-
mation on the physiologic effects of ethanol in pediatric
populations except in acute poisonings when signs of ethanolr Inc. This is an open access article u
rmD, Department of Pharma-
son University, 132 S 10th St,
. Marek).exposure can include hypoglycemia, acidosis, tachycardia, hypo-
thermia, hyporesponsiveness, and disorders of consciousness.3,4
The Food and Drug Administration has set a maximum limit of
0.5% ethanol in oral over-the-counter products intended for
children younger than age 6 years (21 CFR P328 2013). The
American Academy of Pediatrics Committee on Drugs has recom-
mended that the amount of ethanol contained in any preparation
should not be able to produce a blood concentration 425 mg/dL
after a single dose,5 whereas the European Medicines Agency
recently proposed that blood ethanol levels should not exceed
1 mg/dL after a single dose (or a dose of 6 mg/kg) in children
younger than age 6 years.6 These limits are intended to serve as
safety standards, although they are not based on speciﬁc scientiﬁc
evidence.
Ethanol intake secondary to medication administration can
vary widely in pediatric patients. A pilot study of pediatric
intensive care unit patients aged 26 weeks to 15 years in the
United Kingdom found that 26 of 28 patients were prescribed an
ethanol-containing medication with a daily intake of 0.006 to 2.18
mL uncorrected for weight. Authors estimated that these intakes
were equivalent to about 0.07 to 15.2 adult UK alcohol units per
week7 or 0.04 to 8.68 US alcohol units per week (ie, 40.5–121 g/wk).
The United Kingdom considers 8 g to be 1 unit, or standard adult
drink;8 the United States considers 14 g to be 1 unit or standardnder the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
Table I
Ethanol content of select oral pediatric medications.
Drug Ethanol content (%)
Acetaminophen with codeine elixir 7
Chlorothiazide oral suspension 0.50
Cyproheptadine hydrochloride syrup 5
Dexamethasone oral solution 30
Diazoxide oral suspension 7.25
Digoxin oral solution 10
Ferrous sulfate oral drops 0.20
Griseofulvin oral suspension 0.20
Hydroxyzine hydrochloride syrup 0.50
Lasix oral solution 11.50
Maalox oral suspension o0.5
Metoclopramide oral solution o0.1
Nystatin oral suspension r1
Phenobarbital elixir 15
Prednisolone oral solution 2
Propranolol hydrochloride 0.60
Ranitidine oral solution 7.70
Sulfamethoxazole and trimethoprim oral suspension 0.26
Zantac 7.50
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ethanol included nystatin, ranitidine, furosemide, and morphine.
Of 28 patients, 2 who had an intake of 415 UK units/wk (8.47 US
units/wk) were both receiving oral morphine for weaning due to
opioid abstinence. Since the study was completed, ethanol has
been largely removed from oral morphine solutions for pediatric
patients.
A second observational study in a UK neonatal intensive care
unit (NICU) identiﬁed 38 preterm babies over a 1-year period with
complete records that survived to discharge at a single hospital.
Authors documented excipient intake rates from eight commonly
used NICU medications. Two of these medications (iron and
furosemide) contained ethanol as an excipient. Babies were
exposed to 0.2 to 1.8 mL ethanol per week uncorrected for weight.
Correlating to about 1 to 7 adult UK alcohol units/wk9 or 0.57 to
4 US units/wk (ie, 48–56 g/wk), these intake rates are substantial
when you consider that the US weekly recommended limits of
alcohol in adults are 14 units/wk for men and 7 units/wk for
women.10
Ethanol pharmacokinetics in adults
Absorption
Ethanol is a small molecule with both hydrophilic and lip-
ophilic characteristics. It is rapidly absorbed in the stomach (20%)
and intestines (80%) by simple diffusion. Ethanol absorption is
largely dependent on gastric emptying rates because it is absorbed
to a large degree in the duodenum.11 In adults, delayed gastric
emptying brought on by the ingestion of food reduces the
absorption of alcohol independent of the relative macronutrient
content of the meal.12 This phenomenon is the basis for the
commonly employed adage of “not drinking on an empty stom-
ach.” Differences in gastric emptying rates have an inﬂuence on
the shape of the concentration time proﬁle. Absorption rate is
driven primarily by gastric motility, as evidenced by decreases in
both Cmax and AUC at 30 minutes with cigarette smoking13 and a
reduced Cmax and delayed tmax with aspirin administration.14
Similarly, gastric bypass surgery15 and use of promotility drugs16,17
increase peak blood ethanol levels. Absorption differences can also
be linked to the quantity, concentration, and speed at which
ethanol is ingested.18 For example, a drink with 10% to 30% ethanol
is absorbed more rapidly than a more dilute drink; but drinks
430% ethanol are absorbed more slowly due to gastric irritation.19
Ethanol is metabolized presystemically in the gastric mucosa atlow ethanol doses (0.3g/kg or 0.15g/kg);20,21 but the magnitude
and importance of gastric ﬁrst pass metabolism is debated.22
Distribution
Following absorption, ethanol readily distributes into tissues
and body ﬂuids and does not exhibit any protein binding. Its
volume of distribution is relative to water content, which is
partially responsible for age- and sex-related differences in phar-
macokinetic parameters.23 In adults, total body water content
depends on age, weight, and gender, and is approximately 50%
to 60% of total body weight in men and 45% to 55% of body weight
in women.24 Ethanol crosses the blood–brain and placental bar-
riers, due in part to its amphiphilic nature.25 It has been described
as following a 2-compartment model, with its distribution
depending on elements that govern peripheral circulation, includ-
ing vasoconstriction, hormone changes, muscular activity, temper-
ature, and circulatory impairment.23
Metabolism
Less than 10% of ethanol is excreted in the breath, sweat, and
urine. The remaining fraction of ingested ethanol is metabolized to
acetaldehyde by 1 of 3 systems: alcohol dehydrogenase (ADH),
microsomal ethanol-oxidizing system (MEOS), or catalase.
Acetaldehyde is subsequently oxidized to acetate by aldehyde
dehydrogenase (ALDH). Acetate leaves the liver and is converted
to acetyl-coenzyme A to ultimately produce carbon dioxide and
water. A small fraction of ethanol is cleared by nonoxidative
pathways and involves ethanol conjugation to endogenous sub-
strates such as fatty acids, phospholipids, sulfate, or glucuronic
acid to form fatty acid ethyl esters, phosphaditylethanol, ethyl
sulfate, and ethyl glucuronide.26,27 These metabolites have a longer
half-life than ethanol and have been used as biomarkers of ethanol
consumption and chronic ethanol use, although none are optimal
for this purpose.28
A 70-kg adult can metabolize approximately 170 to 240 g of
ethanol a day.26 Ethanol clearance is easily saturated and is best
described by Michaelis-Menton (saturation) kinetics. At high
concentrations, ethanol is eliminated by zero-order kinetics at a
rate of approximately 20 mg/dL/h depending on previous exposure
and genetic differences.29 Nontolerant individuals can eliminate
ethanol at a rate of about 10 to 25 mg/dL/h,23 whereas habitual
drinkers can have elimination rates of Z30 mg/dL/h.30 Ethanol
elimination switches from zero-order to ﬁrst-order kinetics when
blood ethanol concentrations begin to drop below 1 to 3 mM (4.6–
13.8 mg/dL).31,32 Covariates that inﬂuence ethanol clearance
include body weight, age, dissolved oxygen concentration,33 and
genetic polymorphisms (Table II).34
ADH accounts for the bulk of ethanol’s oxidative metabolism.
It has a wide spectrum of activity, oxidizing many primary and
secondary alcohols.26 ADH is primarily located in the liver, but can
be found to a lesser extent in the gastrointestinal tract, kidneys,
nasal mucosa, testes, and uterus.26 Humans have 5 main classes of
ADH enzymes (Class I–V), each with differing afﬁnities for ethanol.
Class I ADH is primarily found in the liver and contributes the most
to ethanol metabolism.26 Class I isozymes form hetero- or homo-
dimers with α, β, and γ subunits, and are coded by ADH1, ADH2,
and ADH3 genes, respectively. All Class I ADH isoforms, except the
αα and relatively uncommon β3β3 isoforms, have Michaelis con-
stant (Km) values r1 mM and therefore become saturated
quickly. The Km of αα and β3β3 isoforms are about 4.2 and 24
mM, respectively.26 Class II ADH is also located in the liver and
helps in metabolizing higher ethanol concentrations due to its
higher Km (34 mM) for ethanol.31 Class III ADH is distributed
throughout the body, has a high Km for ethanol (42 mM), and is
important in metabolizing other alcohols.26 Class IV ADH is
Table II
Sources of variability in adult ethanol pharmacokinetics.
Parameter Mechanism Corresponding covariates
Absorption Gastric motility Fed state, concomitant medications, tobacco
Distribution Negligible protein binding, correlation to total body water Age, sex, body weight
Metabolism Enzymatic polymorphism of ADH and ALDH Ethnicity, sex
Induction of metabolism by CYP2E1 Frequency of ethanol consumption
ADH ¼ alcohol dehydrogenase; ALDH ¼ aldehyde dehydrogenase; CYP ¼ cytochrome P450.
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only been recognized at the mRNA level. Overall in vivo metabo-
lism by ADH is dependent on both enzyme kinetics and on the
relative concentration of each isoform. ADH has numerous poly-
morphic forms, which are described extensively.35,36
MEOS is a cytochrome P450-dependent system involving
cytochromes P4502E1 (CYP2E1), P4501A2 (CYP1A2), and
P4503A4 (CYP3A4).37 MEOS accounts for o10% of ethanol oxida-
tion by the liver.31 Within the MEOS system, CYP2E1 plays the
major role in metabolism.38 CYP2E1 has broad substrate speciﬁcity
and plays an important role in detoxiﬁcation and defense mech-
anisms against xenobiotics.39 It has a relatively high Km for
ethanol (10 mM) and is particularly important at high ethanol
concentrations.37 Ethanol increases CYP2E1 levels upon chronic
administration, and microsomal levels are up to 4-fold higher in
alcoholics compared with nondrinkers.40 CYP2E1 induction is
primarily due to posttranscriptional protein stabilization against
degradation.41 In chronic ethanol administration, CYP2E1
increases ethanol clearance and contributes to metabolic toler-
ance.42 CYP2E1 metabolism generates reactive oxygen species
from molecular oxygen, and has been linked to ethanol-induced
hepatotoxicity.38,41
Catalase is an antioxidant enzyme that degrades hydrogen
peroxide into water and oxygen. It can oxidize a wide variety of
compounds, including ethanol, with the use of hydrogen peroxide.
Although catalase is widely distributed in the body, the pathway is
limited by the low amounts of hydrogen peroxide in the body. The
catalase pathway accounts for about 2% of ethanol metabolism.26
Catalase accounts for a small percentage of the overall metabolism
of ethanol, but it has been proposed to play an important role in
the local production of acetaldehyde in the brain.43,44
ALDH enzymes irreversibly oxidize acetaldehyde in a nicotina-
mide adenine dinucleotide phosphate-dependent manner. To date,
19 human ALDH isozymes have been identiﬁed, with cytosolic
ALDH1A1 and mitochondrial ALDH2 being the most important for
acetaldehyde metabolism.45 They have Km values of 50 to 180 uM
and o1 uM, respectively.45 Under normal physiologic conditions
acetaldehyde concentrations are low, and ALDH2 is the primary
isoform responsible for oxidizing acetaldehyde to acetate.31
ALDH1A1 and ADH2 are distributed throughout the body, includ-
ing the liver, kidney, and brain.45
Elimination
The majority of ethanol is metabolized, with o10% excreted
unchanged by exhalation, urine, and sweat. Further, after a single
dose of ethanol, approximately 0.7% to 1.5% of ethanol is excreted
unchanged in the urine.46
Neonate Pharmacokinetics: Focus on Ethanol absorption, distribution,
metabolism, and excretion Pathways
Neonates are in a period of rapid growth and maturation,
leading to altered pharmacokinetics. These changes may translate
to increased toxicity or reduced efﬁcacy of drugs. Numerous
reviews are available on the subject of neonate and infantpharmacokinetics.47–50 Figure 1 identiﬁes physiologic factors in
neonates having the potential to affect the absorption, distribution,
metabolism, and excretion of ethanol when compared with adults.
Absorption
Generally, neonates have prolonged and variable gastric emp-
tying times compared with adults,51,52 and predicting oral absorp-
tion can be difﬁcult during this epoch. Additionally, changes in
splanchnic blood ﬂow during this period can alter the concen-
tration gradient across the intestinal mucosa, leading to altered
absorption rates.53 Ethanol absorption is largely dependent on
gastric emptying rates and the rate and extent of absorption may
therefore be reduced in neonates. Absorption is further compli-
cated by extrauterine factors, including the rate of ethanol con-
sumption and food or drug effects. In addition to normal
maturation and development, diseases are likely to have an
inﬂuence on oral absorption and must be considered on a case-
to-case basis.
Distribution
Neonates have a very different body composition than adults.
The total body water content decreases from about 92% of total
body weight in premature newborns to 75% in full-term newborns
and 60% by age 1 year.54,55 It does not approach adult values until
age 12 to 13 years.55 In full-term neonates, total body fat increases
from approximately 12% to 16% of total body weight to about 20%
to 25% of body weight at age 1 year.55 These dynamic body
composition changes have the potential to affect drug levels. For
example, hydrophilic drugs generally have an increased volume of
distribution in neonates on a per kilogram body weight basis, so
higher doses may be required to achieve similar peak concen-
trations. Ethanol may therefore have a larger apparent volume of
distribution and lower plasma concentrations in neonates when
compared to adults. Other factors that inﬂuence drug distribution
include regional blood ﬂow, organ perfusion, permeability of
membranes, and cardiac output.56 Cardiac output is redistributed
in the ﬁrst 5 days of life to metabolically active regions, such as the
brain.53 Altered blood ﬂow rates and increased perfusion to the
brain may inﬂuence ethanol distribution in neonates.
Metabolism
In general, neonatal clearance mechanisms and metabolizing
enzymes are immature. ADH activity is reported to be present in
neonates and infants from age 9 days to 2 months, but it accounts
for o20% of adult enzymatic activity (milliunits per gram liver
wet weight of crude fetal and adult livers).57 One report esti-
mated ADH content to be about 10-fold lower in perinatal infants
than in adults (0.11 ± 0.09 vs 1.00 ± 0.37 g/kg liver wet weight
respectively; n ¼ 7 perinatal infants), with the αα isoenzyme
predominating.58 ADH activity does not reach adult levels until
about age 5 years.57 The work of Smith et al59 shows the
progressive expression of ADH during development. Neonatal
CYP enzymes have signiﬁcant differences in their mRNA, protein,
and enzyme activity when compared with adults.60 CYP2E1 levels
increase within a few hours of birth and gradually reach 30% to
Table III
Ethanol clearance estimates in pediatric patients from case reports.
Ethanol Exposure
Absorption
DistributionMetabolism
Elimination
Absorption
• Slow and irregular gastric emptying
• Blood flow changes
Distribution
• Increased total body water
• Decreased total body fat
• Blood flow changes
Metabolism
• Decreased ADH levels
• Decreased CYP2E1 levels
• Equal or increased catalase levels
Elimination
• Decreased renal function
Alcohol 
Dehydrogenase
CYP2E1 Catalase
Acetaldehyde
Acetyl CoA
Aldehyde 
Dehydrogenase
Fatty Acids TCA Cycle Cholesterol
Ketone Bodies
Ethanol
Figure 1. Ethanol disposition. Physiologic factors in neonates having the potential to affect the absorption, distribution, metabolism, and excretion of ethanol when
compared with adults. Red boxes show infant-speciﬁc differences compared with adults.
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may have a greater inﬂuence on neonatal ethanol metabolism.
Autopsy examination reveals equal (0.32 ± 0.03 vs 0.37 ± 0.20 g/kg
wet liver weight; P ¼ not signiﬁcant; n ¼ 4 perinatal infants) or
greater catalase content (1.55 ± 0.48 vs 0.37 ± 0.02 g/kg liver wet
weight; P o 0.05; n ¼ 3 perinatal infants) in perinatal infants
compared with adults.58
Neonates may be more susceptible to drug–excipient or exci-
pient–excipient pharmacokinetic interactions when compared
with adults because of their reduced metabolic activity. For
example, the Food and Drug Administration issued a warning in
2011 to avoid Kaletra (lopinavir/ritonavir) oral solution in prema-
ture babies until 14 days after their due date, or in full-term babies
younger than age 14 days due to multiple postmarketing cases of
life-threatening events.63 Kaletra oral solution contains 42.4% (v/v)
ethanol and 15.3% (w/v) propylene glycol, both of which are
metabolized by ADH in the liver. Thus, a theoretical pharmacoki-
netic interaction between ethanol and propylene glycol may
explain Kaletra’s toxicity in newborns whom have reduced ADH
activity.Study design Sample
size
Postnatal age
(mo)
Estimated clearance
(mg/dL/h)
Source
Postnatal exposure
Case report 1 18 28.7 69
Retrospective
chart review
8 18-156 28.4 70
Case report 1 0.95 10-25 71
Case report 1 1.15 17.1-21.2 72
Case report 1 7 49.7 74
Perinatal exposure
Case report 1 o1 d 11.3 75
Case report 1 o1 d 17.3 75
Review 47 o1 d 8.3 76Elimination
Renal clearance is determined by the combination of glomer-
ular ﬁltration (GFR), tubular secretion, and reabsorption. After
birth, GFR matures more quickly than tubular function,64 although
GFR does not approach adult levels until age 1 to 2 years.65 Tubular
secretion and reabsorption rates are about 20% to 30% of adult
values at birth.66 Drugs primarily eliminated by the kidney may
have an increased half-life during the neonatal period when
compared with adults. Renal elimination of ethanol in neonates
may be decreased, but renal elimination accounts for o5% of
ethanol elimination.Case reports of ethanol toxicity in pediatric patients
A MeSH search on PubMed of ethanol AND infant OR newborn
infant returned 4500 hits, many with prenatal components,
intoxications, and accidental exposures, or animal data. Numerous
case reports are available describing ethanol toxicity in pediatrics.
Ethanol can be found in alcoholic beverages, medications, and
household products such as hand sanitizers, mouthwash, and
cosmetics. One of the most common adverse effects of ethanol
intoxication in pediatric patients is hypoglycemia, due to reduced
glycogen stores.67 The lethal dose of ethanol is reported to be 3 g/kg
in children.68
We describe several case reports, including clearance data for
ethanol in neonates and infants (Table III).
A study from Charity Hospital in Louisiana described four
pediatric patients having ethanol levels 4300 mg/dL.69 One
patient, an 18-month old boy had serial blood ethanol levels
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on 3 subsequent blood draws, authors concluded that the ethanol
level decreased at a rate of 28.7 mg/dL/h assuming zero-order
elimination.69
In a retrospective chart review, authors identiﬁed 8 children
(aged 18 months to 13 years) with ethanol ingestion and at least
2 documented blood ethanol levels from Calgary-area hospitals.70
Authors concluded that the mean rate of decline of ethanol in
these children was 28.4 mg/dL/h, nearly twice the rate of adults.70
One of these patients, an 18-month old girl had an initial ethanol
level 189 mg/dL and a calculated clearance of 41 mg/dL/h assum-
ing zero-order elimination. Four of the 8 patients had a second
ethanol level of 0, indicating that ethanol may be eliminated more
rapidly than was reported.
A study from the Children’s Hospital of Philadelphia described a
29-day old baby with an initial ethanol level 301 mg/dL.71
The child had a mild clinical course with subtle neurologic
symptoms and made a full recovery. From serial blood alcohol
measurements, authors estimated ethanol was cleared at a rate of
10 to 25 mg/dL/h.
A case report described a 5-week old African American boy
admitted to an emergency department with an initial serum
ethanol level of 270 mg/dL.72 The infant recovered successfully
and was “back to normal” within 24 hours. Based on three
subsequent blood ethanol measurements (1 of which was unde-
tectable for ethanol) they estimated an ethanol clearance of 17.1 to
21.2 mg/dL/h assuming zero-order elimination.
McCormick et al73 described 2 cases of ethanol intoxication in
infants younger than age 2 months in a California pediatric
emergency department.73 The infants presented with acute life-
threatening events and had initial ethanol levels 278 mg/dL and
405 mg/dL, respectively. Subsequent ethanol levels were drawn
following admission and authors concluded that ethanol follows
Michaelis-Menten kinetics, changing from zero-order to ﬁrst-order
elimination at about 225 mg/dL. As described earlier in this review,
elimination switches from zero-order to ﬁrst-order at around
1 mM (4.6 mg/dL) in adults.
Finally, a study from the Children’s Hospital of Pittsburg
described a 7-month old infant with an initial ethanol level of
183 mg/dL .74 The infant did not develop any complications, and
was found to have an ethanol elimination rate of 49.7 mg/dL/h
based on 3 blood draws (1 of which was undetectable for ethanol).
In addition to alcohol toxicity studies in pediatrics, studies on
perinatal alcohol exposure are also available. The pharmacoki-
netics described in these studies may be complicated by the
development of tolerance. A case study by Kvigne et al75 described
2 neonates with chronic alcohol exposure in utero. Mothers of the
neonates had documented alcohol exposure before, during, and
after their pregnancies. The ﬁrst neonate had an ethanol level of
38.4 mg/dL at 129 minutes after birth and a calculated ethanol
elimination rate of 11.3 mg/dL/h. The second neonate had an
ethanol level 246.5 mg/dL at 67 minutes after birth and was found
to have an elimination rate of 17.3 mg/dL/h. The ﬁrst infant did not
show any physical signs of fetal alcohol syndrome; the second
infant was diagnosed with fetal alcohol syndrome.
In a recent review that identiﬁed 47 newborns with perinatal
alcohol exposure,76 newborns had a mean blood ethanol concen-
tration of 79.6 mg/dL (range ¼ 5–212 mg/dL) at birth and a mean
elimination rate of 8.3 mg/dL/h (range ¼ 2.5–20 mg/dL/h).
A comparison of neonate and maternal elimination of alcohol
found that the neonates eliminated it at a rate that was one-third
to twice that of their mothers.
We note that all of these reports should be interpreted with
caution. Most calculated ethanol elimination assuming zero-order
elimination and may only have used 2 time points. Furthermore,
with the exception of the acute poisonings, they provided littleinformation on the effects of ethanol in pediatric patients, espe-
cially for low chronic doses of ethanol. From limited case reports, it
is obvious that there is a great deal of interindividual variability in
ethanol clearance in neonates and infants.Measurement of ethanol in blood
In adults, numerous analytic techniques are available for
determining blood ethanol levels. Methods can be classiﬁed as
chemical, enzymatic or chromatographic77 with enzymatic and
chromatographic methods being the most popular. Enzymatic
assays are often employed in the clinic. When enzymatic assays
are used to quantify ethanol levels, ADH and oxidized nicotina-
mide adenine dinucleotide (NAD+) are added to blood samples to
produce acetaldehyde and reduced nicotinamide adenine dinu-
cleotide (NADH) from ethanol metabolism. The reduced coenzyme
(NADH) can be monitored photometrically, ﬂurimetrically, or
voltammetrically and is proportional to the ethanol concentration
in the sample.77 Gas chromatography (GC) is often used in forensic
labs and is the gold standard for determining blood ethanol levels.
GC is speciﬁc for ethanol and can concurrently measure other
volatile alcohols such as methanol and isopropranol.78 Measuring
blood ethanol levels in neonate presents a technical challenge
because neonates have lower blood volumes than adults. Often,
microassays and microanalytical methods must be used to allow
for small volumes and sparse sampling of blood. Recently, Cordell
et al79 developed a sensitive and reproducible headspace GC-mass
spectrometry method for volatile organic compounds using micro-
volume samples (r100 uL).79 The GC-mass spectrometry method
was linear from 0.02 to 10 mg/dL, with limits of detection between
0.01 to 0.02 mg/dL and lower limits of quantiﬁcation between 0.05
to 0.1 mg/L.
Ethanol is produced endogenously at low levels from reduction
of the metabolic byproduct acetaldehyde via a reversible ADH
reaction and through carbohydrate fermentation by gut ﬂora.
Candida albicans, which plays an important role in intestinal
fermentation, has been shown to produce ethanol at a maximum
rate of 1 mg/h/g intestinal content.80 Endogenous ethanol levels
have substantial interindividual differences and levels vary
depending on the methods used to measure ethanol. In healthy
individuals, endogenous ethanol levels have been reported to
range from below detection limits to 1.6 mg/mL (0.16 mg/dL).81
Metabolic conditions such as diabetes,82 short bowel syndrome,83
and nonalcoholic steatohepatitis can elevate endogenous ethanol
levels.84 In a small study of 10 healthy volunteers, ethanol levels
ranged from 0 to 0.377 mg/mL (0–0.0377 mg/dL) using a sensitive
gas chromatography method.85Discussion
The pathology and pathophysiology of adverse neurodevelop-
ment due to antenatal ethanol exposure has been well
described.86,87 Ethanol exposure during gestation has been shown
to cause widespread damage throughout the brain, interfering
with cell proliferation, migration, growth and differentiation, and
cell death depending on the time and levels of alcohol exposure.88
However, the inﬂuence of ethanol on nervous system development
in the postnatal period is less clear. There remains a lack of
evidence of the adverse events of ethanol in the developing brain
of infants. Challenges to establishing a dose that is considered to
be harmful include variability in doses administered, likely
changes in ethanol disposition based on developmental factors,
difﬁculty in choosing a short term outcome to measure, and lack of
long-term follow-up to assess outcomes. The applicability of
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massive doses of ethanol.
Due to the lack of evidence on how ethanol affects developing
brains, clear recommendations are impossible at this time, but it
seems reasonable for clinicians to minimize the use of ethanol-
containing solutions in neonates whenever possible. Furthermore,
clinicians should work to reduce ethanol in existing formulations. It is
acknowledged that ethanol has been used for years, and that there
are certainly circumstances where the beneﬁt of ethanol in a
medication outweighs potential adverse effects. When ethanol
exposure cannot be avoided, we must be cognizant of potential
pharmacokinetic and pharmacodynamic drug interactions, especially
in NICU patients taking multiple medications. Similar to adults, NICU
patients are at risk of enhanced sedative and hypnotic effects on the
central nervous system with agents such as barbiturates and benzo-
diazepines. Additionally, it may not be feasible to watch for subtle
neurologic deﬁcits, but it is possible to watch for more obvious
adverse events, such as hypoglycemia, with ethanol use.
The pharmacodynamics of ethanol and the nature of an indi-
vidual’s response may differ between neonates and adults. Although
little is known in this regard as it applies to neonates, we do know
that in adults, ethanol affects a large number of membrane proteins
involved in signaling pathways. Speciﬁcally, ethanol enhances the
action of γ-aminobutyric acid at γ-aminobutyric acidA receptors and
inhibits the ability of glutamate to open N-methyl-D-aspartate
cation channels.89 In addition, it has effects on calcium channels,
dopamine and serotonin receptors, the hypothalamic-pituitary-
adrenal axis, and the central adrenergic system.90
Acetaldehyde accumulation in the periphery contributes to
some of the adverse effects in adults associated with drinking,
including nausea, vomiting, vasodilation, and hypotension.91 For
most people, acetaldehyde does not accumulate in the periphery
due to the high efﬁciency of ALDH; although genetic polymor-
phisms in ALDH can lead to increased sensitivity to ethanol.92 Due
to its nonpolar characteristics, acetaldehyde is extensively reab-
sorbed from the renal tubules and the route of elimination is
primarily by metabolism. Acetaldehyde is a highly reactive mole-
cule that can create adducts with proteins, lipids, and DNA.93
These adducts play a role in alcoholic liver disease,93 and there is
evidence of adducts in other tissues such as the brain, gut, muscle,
heart, and red blood cells.94 Current evidence suggests that
acetaldehyde, formed locally in the brain from ethanol metabo-
lism, crosses the blood–brain barrier when the ALDH enzymatic
barrier is saturated.44 In rodents, catalase has been proposed to
account for 60% of ethanol oxidation in the brain, whereas CYP2E1
may account for 20% of ethanol oxidation in the brain.43 Animal
studies have shown that acetaldehyde adducts are expressed in
neonatal brains exposed to ethanol in utero.95 As described above,
neonates may have increased catalase levels compared with
adults, but the localization and potential effects on ethanol
oxidation in the brain are largely unknown.
The potential dysphoric effects of acetate produced after
ethanol ingestion have been recently been explored.96 Acetate
modulates the adenosine receptor. Caffeine, an adenosine receptor
antagonist, is used frequently in neonatology and has well-
described beneﬁcial effects in ethanol-induced headache. The
exact implications of such are unclear.
Questions remain about many of the other ways that ethanol may
affect infants. In particular, little is known about the psychoactive
effects of chronic ethanol administration in neonates. In neonates,
some tissues may be more or less sensitive to ethanol, regardless of
drug concentrations, based on their developmental stage, concom-
itant diseases, and treatment modalities. And for many drugs,
including ethanol, the effect of ontogeny on the pharmacodynamics
of the drug is not well established.56 Additionally, there are limited
pharmacogenetic studies in neonates and infants.We aimed to raise awareness of ethanol use as an excipient in
pediatric medications. Not all excipients are safe, as has been seen
with the use of benzyl alcohol and propylene glycol toxicity.97,98
Safety studies of excipients can be more challenging than those of
the active pharmaceutical ingredient because exposure is generally
less controlled and excipients may originate from numerous dose
forms taken over various time periods. Although challenging,
safety and pharmacokinetic studies of excipients in neonates are
feasible, as has been demonstrated with propylene glycol.99,100
To help establish safe limits for excipients, the European and
United States Paediatric Formulation Initiatives have developed a
Safety and Toxicity of Excipients for Pediatrics (STEP) database.101
The database aims to centralize any available excipient safety and
toxicity data, and to organize these data into a searchable, publicly
available system. Similarly, the European Study of Neonatal Exci-
pient Exposure project aims to assess neonatal exposure to
potentially toxic excipients.102 As a part of the project, blood
samples will be collected from neonates receiving select excipients
(ie, propylene glycol, ethanol, propylhydroxybenzoate, sodium
benzoate, polysorbate 80, and sorbitol) to determine how exci-
pients are handled in neonates. Both the STEP database and
European Study of Neonatal Excipient Exposure project have
included ethanol as a prioritized excipient, highlighting the
importance of additional research on ethanol use in neonates
and infants.Conclusions
The STEP database along with available pharmacokinetic data
may provide sufﬁcient evidence for a more rational use of ethanol
in this venerable population. Until the effects of ethanol have been
more clearly deﬁned, formulations using ethanol should be mini-
mized and the risk–beneﬁt assessment should be taken into
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